Oxford BioDynamicsSTU:LMQ Net Margin % is -1,063.25% as of Sep. 2025. The stock has 4 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Oxford BioDynamics ranks worse than 91.67% on this metric.
The historical rank and industry rank for Oxford BioDynamics's Net Margin % or its related term are showing as below:
STU:LMQ'
s Net Margin % Range Over the Past 10 Years
Min: -4357.14 Med: -986.14 Max: -158.57
Current: -1018.54
STU:LMQ's Net Margin % is ranked worse than 91.67% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.405
vs STU:LMQ: -1018.54
Oxford BioDynamics (STU:LMQ) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Oxford BioDynamics Net Margin % Related Terms
Oxford BioDynamics Net Margin % Historical Data
* Premium members only.
The historical data trend for Oxford BioDynamics's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:LMQ vs TMO, DHR, IDXX: Net Margin % Comparison
For the Diagnostics & Research subindustry, Oxford BioDynamics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oxford BioDynamics Net Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Oxford BioDynamics's Net Margin % distribution charts can be found below:
* The bar in red indicates where Oxford BioDynamics's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oxford BioDynamics (STU:LMQ) has a Net Margin % of -1,063.25% as of Sep. 2025. Net margin is the ratio of total net income to net sales. View historical data on Oxford BioDynamics and its competitors. According to the industry distribution chart, Oxford BioDynamics ranks #187 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 91.7%.
Is Oxford BioDynamics' Net Margin % too high?
Oxford BioDynamics' current Net Margin % is -1,063.25%. Based on the distribution chart, Oxford BioDynamics ranks #187 out of 204 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Oxford BioDynamics' Net Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Oxford BioDynamics ranks #187 out of 204 companies for Net Margin %. This places Oxford BioDynamics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Diagnostics & Research company?
A good Net Margin % depends on the Medical Diagnostics & Research industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Oxford BioDynamics and its competitors. Oxford BioDynamics's current Net Margin % is -1,063.25%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oxford BioDynamics stock overvalued right now?
Based on GuruFocus' analysis, Oxford BioDynamics (STU:LMQ) is currently considered Possible Value Trap. The stock's GF Value™ is €0.01, compared to a current price of €0.00 — trading 95% below its estimated fair value. The current Net Margin % is -1,063.25%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Oxford BioDynamics (STU:LMQ), the current Net Margin % is -1,063.25% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Oxford BioDynamics PLC is a biotechnology company focused on advancing personalized healthcare through the development and commercialization of precision medicine tests for serious and impactful diseases. The company is engaged in the commercialisation of proprietary molecular diagnostics products and biomarker research and development. It has two commercially available products: the EpiSwitch PSE (EpiSwitch Prostate Cancer Detection Test) and EpiSwitch CiRT (Checkpoint Inhibitor Response Test) blood tests. The company generates revenue from the sales of proprietary products and biomarker research and development. Geographically, it generates the maximum revenue from the USA.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:LMQ has been successfully added to your 